Adalimumab Therapy for Pyoderma Gangrenosum
Author Information
Author(s): Fonder Margaret A., Cummins Deborah L., Ehst Benjamin D., Anhalt Grant J., Meyerle Jon H.
Primary Institution: Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD
Hypothesis
Can adalimumab effectively treat pyoderma gangrenosum in patients who are refractory to other treatments?
Conclusion
Adalimumab was effective in resolving pyoderma gangrenosum in a patient who did not respond to other treatments.
Supporting Evidence
- The patient had severe pyoderma gangrenosum that progressed despite multiple treatments.
- Adalimumab was initiated after other treatments failed and led to rapid improvement.
- The patient experienced no recurrence of pyoderma gangrenosum during 4 months on adalimumab.
Takeaway
A woman with a painful skin ulcer got better after taking a new medicine called adalimumab, even though other treatments didn't work.
Methodology
Case report and literature review.
Potential Biases
Potential bias due to the subjective nature of case reports.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 38-year-old white woman with inflammatory bowel disease.
Want to read the original?
Access the complete publication on the publisher's website